iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival

– Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program

Read more at globenewswire.com